Marian Tošovský
Marian Tošovský has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Petr Bradna
12nd Department of Internal Medicine-Gastroenterology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Kralove
6 shared publications T. Soukup
Second Department of Internal Medicine-Gastroenterology
3 shared publications- Tomáš Soukup
Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
3 shared publications - Eva Cermakova
Faculty of Medicine in Hradec Králové, Charles University, 500 03 Hradec Králové, Czech Republic
2 shared publications - Jan Toms
Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, 2nd Department of Internal Medicine - Gastroenterology, Hradec Kralove, Czech Republic
2 shared publications C. Andrýs
Department of Clinical Immunology and Allergy, Charles University in Prague, Faculty of Medicine in Hradec Králové and University Hospital
1 shared publication
Latest Publications
- Open Access
- 28 August 2015
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 55 (1) , 109-114
Application of the DETECT algorithm for detection of risk of pulmonary arterial hypertension in systemic sclerosis: data from a Czech tertiary centre
Objective. The early, simple and reliable detection of pulmonary arterial hypertension (PAH) in SSc (DETECT) study described a new algorithm for early detection of PAH in patients with SSc. The aim of this retrospective, single-centre, cross-sectional study was to apply a modified DETECT calculator in patients with SSc in the East Bohemian region, Czech Republic, to assess the risk of PAH and to compare these results with PAH screening based on the European Society of Cardiology/European Respiratory Society (ESC/ERS) 2009 guidelines. Methods. Sixty patients were recruited with a diagnosis of SSc (according to ACR criteria), aged 27–78 years. A modified DETECT algorithm using the modified parameter of (1.4 × right ventricle diameter)2 in place of right atrium area was applied to all patients. Right heart catheterization (RHC) was performed in all patients with an estimated (by echocardiography) increased systolic pulmonary artery pressure ≥50 mm Hg in accordance with the ESC/ERS guidelines; however, RHC was not performed in patients solely recommended for RHC using the modified DETECT algorithm. Results. Using the modified DETECT calculator, 24/58 (41.4%) patients were recommended for RHC, compared with 14/58 (24.1%) when applying the ESC/ERS 2009 guidelines. PAH was diagnosed in 7/58 (12.1%) patients. During follow-up, PAH was diagnosed in six patients. Of these, four were modified DETECT score–positive for 2 years and all for 1 year before PAH diagnosis. Conclusion. The modified DETECT algorithm detects all patients with PAH diagnosed according to ECS/ERS 2009 guidelines and RHC. Data of the 2-year follow-up indicate a possible positive predictive role for the modified DETECT calculator.
- 28 August 2015
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 55 (1) , 109-114
Open AccessApplication of the DETECT algorithm for detection of risk of pulmonary arterial hypertension in systemic sclerosis: data from a Czech tertiary centre
Objective. The early, simple and reliable detection of pulmonary arterial hypertension (PAH) in SSc (DETECT) study described a new algorithm for early detection of PAH in patients with SSc. The aim of this retrospective, single-centre, cross-sectional study was to apply a modified DETECT calculator in patients with SSc in the East Bohemian region, Czech Republic, to assess the risk of PAH and to compare these results with PAH screening based on the European Society of Cardiology/European Respiratory Society (ESC/ERS) 2009 guidelines. Methods. Sixty patients were recruited with a diagnosis of SSc (according to ACR criteria), aged 27–78 years. A modified DETECT algorithm using the modified parameter of (1.4 × right ventricle diameter)2 in place of right atrium area was applied to all patients. Right heart catheterization (RHC) was performed in all patients with an estimated (by echocardiography) increased systolic pulmonary artery pressure ≥50 mm Hg in accordance with the ESC/ERS guidelines; however, RHC was not performed in patients solely recommended for RHC using the modified DETECT algorithm. Results. Using the modified DETECT calculator, 24/58 (41.4%) patients were recommended for RHC, compared with 14/58 (24.1%) when applying the ESC/ERS 2009 guidelines. PAH was diagnosed in 7/58 (12.1%) patients. During follow-up, PAH was diagnosed in six patients. Of these, four were modified DETECT score–positive for 2 years and all for 1 year before PAH diagnosis. Conclusion. The modified DETECT algorithm detects all patients with PAH diagnosed according to ECS/ERS 2009 guidelines and RHC. Data of the 2-year follow-up indicate a possible positive predictive role for the modified DETECT calculator.
- Open Access
- 12 November 2014
- Published by Charles University in Prague, Karolinum Press in Acta Medica (Hradec Kralove, Czech Republic)
- Vol. 57 (2) , 56-61
THE VEGF AND BMP-2 LEVELS IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND THE RELATIONSHIP TO TREATMENT WITH TUMOUR NECROSIS FACTOR ALPHA INHIBITORS
Introduction: Ankylosing spondylitis (AS) is an inflammatory rheumatic disease characterized by the development of osteoproductive changes in the spine which could possibly result in ankylosis. Treatment with tumour necrosis factor alpha (TNFα) inhibitors has proved to be an important step forward in the treatment of this disease, but for the time being it is not clear whether it favourably influences radiographic progression of the disease. Vascular endothelial growth factor most probably plays a role in the development of osteoproductive changes and recently its predictive influence on radiographic progression has been demonstrated. Bone morphogenic protein 2 (BMP-2) participates in the regulation of bone proliferation and its increased serum level has been demonstrated in patients with advanced AS and correlated with the degree of radiographic changes. Aim: The study aims to evaluate the VEGF and BMP-2 levels in patients with ankylosing spondylitis and how these levels relate to the concurrent treatment with TNFα inhibitors. Methods: Sera were evaluated from patients at the Rheumatologic Clinic of the Hradec Králové Faculty Hospital who fulfilled the modified New York Criteria for AS (n = 55). In these patients, the parameters of the activity of the disease (BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, CRP = C-reactive protein) and the concurrent therapy (TNFα inhibitors, n = 21, vs. non-anti TNFα, n = 34) were recorded. The levels of VEGF and BMP-2 were analyzed using the ELISA method. Results: In patients treated with TNFα inhibitors, a significantly lower VEGF level was found when compared to untreated patients (140.3 (109.4; 262.2) vs. 261 (172.4; 396.6) pg/ml; p = 0.02). No difference was found between BMP-2 levels in both groups (treated vs. untreated patients) (254.8 (2301; 267.3) vs. 261.1 (248.6; 273.5) pg/ml; p = 0.24). A correlation analysis did not reveal any relationship between VEG F and BMP-2 (r = 0.057; p = 0.68). Serum levels of VEGF correlated with serum levels of CRP (r = 0.56; p = 0.00001) and the BASDAI value (r = 0.33; p = 0.015). Conclusion: Significantly lower VEGF levels were found in patients treated with TNFα inhibitors versus the untreated patients. These findings are in harmony with some hitherto published analyses and may give evidence of a favourable effect of TNFα inhibitors on radiographic progression. Neither influence on the BMP-2 level by treatment with TNFα inhibitors nor correlation with VEGF levels was demonstrated.
- 12 November 2014
- Published by Charles University in Prague, Karolinum Press in Acta Medica (Hradec Kralove, Czech Republic)
- Vol. 57 (2) , 56-61
Open AccessTHE VEGF AND BMP-2 LEVELS IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND THE RELATIONSHIP TO TREATMENT WITH TUMOUR NECROSIS FACTOR ALPHA INHIBITORS
Introduction: Ankylosing spondylitis (AS) is an inflammatory rheumatic disease characterized by the development of osteoproductive changes in the spine which could possibly result in ankylosis. Treatment with tumour necrosis factor alpha (TNFα) inhibitors has proved to be an important step forward in the treatment of this disease, but for the time being it is not clear whether it favourably influences radiographic progression of the disease. Vascular endothelial growth factor most probably plays a role in the development of osteoproductive changes and recently its predictive influence on radiographic progression has been demonstrated. Bone morphogenic protein 2 (BMP-2) participates in the regulation of bone proliferation and its increased serum level has been demonstrated in patients with advanced AS and correlated with the degree of radiographic changes. Aim: The study aims to evaluate the VEGF and BMP-2 levels in patients with ankylosing spondylitis and how these levels relate to the concurrent treatment with TNFα inhibitors. Methods: Sera were evaluated from patients at the Rheumatologic Clinic of the Hradec Králové Faculty Hospital who fulfilled the modified New York Criteria for AS (n = 55). In these patients, the parameters of the activity of the disease (BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, CRP = C-reactive protein) and the concurrent therapy (TNFα inhibitors, n = 21, vs. non-anti TNFα, n = 34) were recorded. The levels of VEGF and BMP-2 were analyzed using the ELISA method. Results: In patients treated with TNFα inhibitors, a significantly lower VEGF level was found when compared to untreated patients (140.3 (109.4; 262.2) vs. 261 (172.4; 396.6) pg/ml; p = 0.02). No difference was found between BMP-2 levels in both groups (treated vs. untreated patients) (254.8 (2301; 267.3) vs. 261.1 (248.6; 273.5) pg/ml; p = 0.24). A correlation analysis did not reveal any relationship between VEG F and BMP-2 (r = 0.057; p = 0.68). Serum levels of VEGF correlated with serum levels of CRP (r = 0.56; p = 0.00001) and the BASDAI value (r = 0.33; p = 0.015). Conclusion: Significantly lower VEGF levels were found in patients treated with TNFα inhibitors versus the untreated patients. These findings are in harmony with some hitherto published analyses and may give evidence of a favourable effect of TNFα inhibitors on radiographic progression. Neither influence on the BMP-2 level by treatment with TNFα inhibitors nor correlation with VEGF levels was demonstrated.
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 857-858
AB0166 The Levels of Soluble CD163 in Patients with Ankylosing Spondylitis
Background Innate immune cells play an important role in pathogenesis of spondylarthropathies (SpA) since the increased infiltration of macrophages, especially CD163+, has been proven in synovitis tissue in these patients. Objectives To evaluate the levels of soluble CD163 (sCD163) in patients with ankylosing spondylitis in comparison with patients treated for degenerative spinal disease. Methods Levels of sCD163 were measured by enzyme-linked immunosorbent assay in patients with established ankylosing spondylitis according to modified New York criteria (n=55) and were compared with control group - patients treated for degeneratve spinal disease (n=20). Furthermore, we compared the levels of sCD163 in patients with ankylosing spondylitis treated (n=21) and not treated (n=34) with tumor necrosis factor alpha inhibitors. Results The levels of soluble CD163 were significantly increased in group of patients with ankylosing spondylitis as compared with the control group (mean ± SEM 1670,8±91,6 ng/ml vs. 1131,5±80,3 ng/ml, p=0,0013). No significant difference was found between levels of soluble CD163 in patients treated and not treated with tumor necrosis factor alpha inhibitors (mean ± SEM 1805,2±184,8 ng/ml vs. 1587,8±94,4 ng/ml respectively, p=0,52). Conclusions Our finding shows, that CD163+ cells may play role in pathogenesis of spondylarthorpathies, particularly ankylosing spondylitis, and soluble CD163 may be applicable biomarker in this disorder. Acknowledgements Supported by MH CZ –DRO (UHHK, 00179906) Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.4464
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 857-858
AB0166 The Levels of Soluble CD163 in Patients with Ankylosing Spondylitis
Background Innate immune cells play an important role in pathogenesis of spondylarthropathies (SpA) since the increased infiltration of macrophages, especially CD163+, has been proven in synovitis tissue in these patients. Objectives To evaluate the levels of soluble CD163 (sCD163) in patients with ankylosing spondylitis in comparison with patients treated for degenerative spinal disease. Methods Levels of sCD163 were measured by enzyme-linked immunosorbent assay in patients with established ankylosing spondylitis according to modified New York criteria (n=55) and were compared with control group - patients treated for degeneratve spinal disease (n=20). Furthermore, we compared the levels of sCD163 in patients with ankylosing spondylitis treated (n=21) and not treated (n=34) with tumor necrosis factor alpha inhibitors. Results The levels of soluble CD163 were significantly increased in group of patients with ankylosing spondylitis as compared with the control group (mean ± SEM 1670,8±91,6 ng/ml vs. 1131,5±80,3 ng/ml, p=0,0013). No significant difference was found between levels of soluble CD163 in patients treated and not treated with tumor necrosis factor alpha inhibitors (mean ± SEM 1805,2±184,8 ng/ml vs. 1587,8±94,4 ng/ml respectively, p=0,52). Conclusions Our finding shows, that CD163+ cells may play role in pathogenesis of spondylarthorpathies, particularly ankylosing spondylitis, and soluble CD163 may be applicable biomarker in this disorder. Acknowledgements Supported by MH CZ –DRO (UHHK, 00179906) Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.4464
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 291
THU0315 Increasing Proportion of Concomitant Fibromyalgia in Rheumatoid Arthritis Cohort Corresponds to Growing Arthritis Activity Assessed by Composite Indices
Background Fibromyalgia (FM) is well described as a concomitant syndrome that can frequently accompany connective tissue diseases, especially rheumatoid arthritis (RA). In this epoch of modern biologic therapy and RA tight control effort it is essential to count various factors that can impact RA activity or modulate activity assessment. Objectives To compare proportional representation of FM in RA patients cohort according to increasing arthritis activity assessed by composite indices in a regional, monocentric, cross-sectional study. Methods Examination of 120 consecutive patients (pts) with RA was performed in the terciary outpatient rheumatology department. Diagnosis of concomitant FM was established according to ACR criteria (1990). Standard Manual Tender Point Survey was used for the examination of FM tender points. The following data were recorded: demographic data, tender point count (TPC), Fibromyalgia Impact Questionnarie (FIQ) score and RA activity composite indices (DAS-28, CDAI, SDAI). Short Form 36 items (SF-36) and Health Assessment Questionnaire (HAQ) were used for evaluation of quality of life (QOL) and functional disability, respectively. Statistical analysis was based on Student's t-test or Fisher exact test (statistical significance level 0.05). Results Concomitant FM was diagnosed in 25 (20.8%) pts with RA, 4 men and 21 women. Comparing RA without FM (RAF-) and with FM (RAF+), there were no significant differencies in sociodemographic characteristics, laboratory inflammatory markers, RF and ACPA seropositivity. RAF+ pts in comparison to RAF- pts reached significantly higher scores of RA activity (DAS-28 5.35±1.1 vs. 3.67±1.4, pConclusions Concomitant fibromyalgia appears frequently in RA pts and has significant impact on the disease activity assessment and disability level because of altered pain perception. Patients with high disease activity measured by widely used composite indices are usually indicated for more intensive immunosuppressive or biologic therapy. But in this case it is necessary to realize this group contains higher portion of FM pts resulting in risk of wrong therapy reinforcement. Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.5942
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 291
THU0315 Increasing Proportion of Concomitant Fibromyalgia in Rheumatoid Arthritis Cohort Corresponds to Growing Arthritis Activity Assessed by Composite Indices
Background Fibromyalgia (FM) is well described as a concomitant syndrome that can frequently accompany connective tissue diseases, especially rheumatoid arthritis (RA). In this epoch of modern biologic therapy and RA tight control effort it is essential to count various factors that can impact RA activity or modulate activity assessment. Objectives To compare proportional representation of FM in RA patients cohort according to increasing arthritis activity assessed by composite indices in a regional, monocentric, cross-sectional study. Methods Examination of 120 consecutive patients (pts) with RA was performed in the terciary outpatient rheumatology department. Diagnosis of concomitant FM was established according to ACR criteria (1990). Standard Manual Tender Point Survey was used for the examination of FM tender points. The following data were recorded: demographic data, tender point count (TPC), Fibromyalgia Impact Questionnarie (FIQ) score and RA activity composite indices (DAS-28, CDAI, SDAI). Short Form 36 items (SF-36) and Health Assessment Questionnaire (HAQ) were used for evaluation of quality of life (QOL) and functional disability, respectively. Statistical analysis was based on Student's t-test or Fisher exact test (statistical significance level 0.05). Results Concomitant FM was diagnosed in 25 (20.8%) pts with RA, 4 men and 21 women. Comparing RA without FM (RAF-) and with FM (RAF+), there were no significant differencies in sociodemographic characteristics, laboratory inflammatory markers, RF and ACPA seropositivity. RAF+ pts in comparison to RAF- pts reached significantly higher scores of RA activity (DAS-28 5.35±1.1 vs. 3.67±1.4, pConclusions Concomitant fibromyalgia appears frequently in RA pts and has significant impact on the disease activity assessment and disability level because of altered pain perception. Patients with high disease activity measured by widely used composite indices are usually indicated for more intensive immunosuppressive or biologic therapy. But in this case it is necessary to realize this group contains higher portion of FM pts resulting in risk of wrong therapy reinforcement. Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.5942
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 1001
AB0591 Acute Respiratory Failure – the Reason for Urgent Rheumatologic Examination?
Background Acute respiratory failure is a reason for urgent admission to ICU. Statistical data show, that about 10 percent of deaths of respiratory failure patients on ICU is caused by diffuse alveolar hemorrhage syndrome (DAH). Barring infection, coagulation defects or oncological therapy complications, systemic connective tissue diseases must be considered as a reason. Less frequently there are patients with known systemic disease, more frequently DAH is the first manifestation of connective tissue disease, especially systemic vasculitis or SLE. Methods During 8 years 24 cases of diffuse alveolar hemorrhage in rheumatologic diseases were treated, 22 on ICU. 21 of them needed artificial ventilation. We observed the symptoms of preceded systemic disease, autoantibodies in time of DAH, hospital mortality and follow up of patients. Results 13 women and 11 men were affected, average age was 52,6 (21-74) years. Only in 32% of them had known diagnosis of systemic connective tissue disease before episode of alveolar hemorrhage. Diagnose of DAH was assessed by bronchoscopy with examination of bronchoalveolar lavage fluid and X-ray or CT results. 21 patients needed artificial ventilation.Most frequent immunological feature was ANCA antibody in 75% of our group. Proteinase -3 specificity was present in 58%, myeloperoxidase in 16% of our patients. ANA antibodies were founded in 21% of our patients, in one patient there was atypical anti GBM antibodies.Antiphospholipid antibodies were not present. Negative results had 20,8% of our group. Patients were treated by pulse methylprednisolone therapy, plasmapheresis, and i.v. Cyclophosphamide or i.v. immunoglobulins in cases where immunosuppressive therapy was contraindicated. Hospital mortality was 42 percent (10 patients). 14 patients are followed on outpatient base, in 3 of them chronic hemodialysis for irreversible renal failure is necessary, Early diagnosis and start of intensive immunomodulating therapy were one of crucial factors for survival of this life-threatening complication, however intensive immunosuppression is high-risky in patients with artificial ventilation support. Conclusions Diffuse alveolar hemorrhage is one of the important reasons of acute respiratory failure. In significant part of such patients the systemic connective tissue disease, mostly systemic vasculitis, is the cause of complication. Serious episode of DAH may be the first manifestation of rheumatologic disease. Bronchoscopic examination for DAH may be performed as early as possible, therefore early start of immunosuppressive therapy is crucial for survival of such patients. Outside of bronchoscopy instant assessment of ANCA antibodies is helpful. References West S, Arulkumaran N, Ind PW, Pusey CD Diffuse alveolar haemorrhage in ANCA-associated vasculitis. Intern Med. 2013;52(1):5-13. Acknowledgements Supported by MH CZ - DRO (UHHK, 00179906) Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.4884
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 1001
AB0591 Acute Respiratory Failure – the Reason for Urgent Rheumatologic Examination?
Background Acute respiratory failure is a reason for urgent admission to ICU. Statistical data show, that about 10 percent of deaths of respiratory failure patients on ICU is caused by diffuse alveolar hemorrhage syndrome (DAH). Barring infection, coagulation defects or oncological therapy complications, systemic connective tissue diseases must be considered as a reason. Less frequently there are patients with known systemic disease, more frequently DAH is the first manifestation of connective tissue disease, especially systemic vasculitis or SLE. Methods During 8 years 24 cases of diffuse alveolar hemorrhage in rheumatologic diseases were treated, 22 on ICU. 21 of them needed artificial ventilation. We observed the symptoms of preceded systemic disease, autoantibodies in time of DAH, hospital mortality and follow up of patients. Results 13 women and 11 men were affected, average age was 52,6 (21-74) years. Only in 32% of them had known diagnosis of systemic connective tissue disease before episode of alveolar hemorrhage. Diagnose of DAH was assessed by bronchoscopy with examination of bronchoalveolar lavage fluid and X-ray or CT results. 21 patients needed artificial ventilation.Most frequent immunological feature was ANCA antibody in 75% of our group. Proteinase -3 specificity was present in 58%, myeloperoxidase in 16% of our patients. ANA antibodies were founded in 21% of our patients, in one patient there was atypical anti GBM antibodies.Antiphospholipid antibodies were not present. Negative results had 20,8% of our group. Patients were treated by pulse methylprednisolone therapy, plasmapheresis, and i.v. Cyclophosphamide or i.v. immunoglobulins in cases where immunosuppressive therapy was contraindicated. Hospital mortality was 42 percent (10 patients). 14 patients are followed on outpatient base, in 3 of them chronic hemodialysis for irreversible renal failure is necessary, Early diagnosis and start of intensive immunomodulating therapy were one of crucial factors for survival of this life-threatening complication, however intensive immunosuppression is high-risky in patients with artificial ventilation support. Conclusions Diffuse alveolar hemorrhage is one of the important reasons of acute respiratory failure. In significant part of such patients the systemic connective tissue disease, mostly systemic vasculitis, is the cause of complication. Serious episode of DAH may be the first manifestation of rheumatologic disease. Bronchoscopic examination for DAH may be performed as early as possible, therefore early start of immunosuppressive therapy is crucial for survival of such patients. Outside of bronchoscopy instant assessment of ANCA antibodies is helpful. References West S, Arulkumaran N, Ind PW, Pusey CD Diffuse alveolar haemorrhage in ANCA-associated vasculitis. Intern Med. 2013;52(1):5-13. Acknowledgements Supported by MH CZ - DRO (UHHK, 00179906) Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.4884
- Open Access
- 1 January 2012
- Published by Charles University in Prague, Karolinum Press in Acta Medica (Hradec Kralove, Czech Republic)
- Vol. 55 (1) , 42-46
Case 1‑2012: ANCA Associated Glomerulonephritis in Combination with IgG4 Positive Mediastinal Mass in a Patient with Ankylosing Spondylitis Treated with TNF Alpha Inhibitors
Acta Medica is a scientific journal of Charles University in Prague, Faculty of Medicine in Hradec Kralove
- 1 January 2012
- Published by Charles University in Prague, Karolinum Press in Acta Medica (Hradec Kralove, Czech Republic)
- Vol. 55 (1) , 42-46
Open AccessCase 1‑2012: ANCA Associated Glomerulonephritis in Combination with IgG4 Positive Mediastinal Mass in a Patient with Ankylosing Spondylitis Treated with TNF Alpha Inhibitors
Acta Medica is a scientific journal of Charles University in Prague, Faculty of Medicine in Hradec Kralove
- 30 April 2005
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 6 (1) , 123
W16-P-089 Extracorporal plasmapheresis in the treatment of severe hyperlipidaemia in patient with polymyositis
- 30 April 2005
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 6 (1) , 123
W16-P-089 Extracorporal plasmapheresis in the treatment of severe hyperlipidaemia in patient with polymyositis